$ALHC

KONOWIECKI JOSEPH S sold $525K of ALHC

KONOWIECKI JOSEPH S (EVP, Corporate Affairs) sold 25,000 shares of Alignment Healthcare, Inc. (ALHC) at $21.00 ($0.52M total) on 2026-06-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · KONOWIECKI JOSEPH S
Published Jun 12, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALHC
Neutral
medium confidence
Mentioned
$ALHC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALHCNeutralLow
01

Why it matters

The disclosure adds incremental sentiment information (insider reduced direct holdings) but provides no new operational or financial guidance.

02

Market read

A planned insider sale may cause minor near-term sentiment drift, but it is unlikely to drive a fundamental repricing alone.

03

What to watch

Insider sales can be scheduled regardless of near-term fundamentals; traders should avoid over-weighting this signal without corroborating news (guidance, trial/regulatory updates, financing).

Relevance 4/10Novelty 5/10Timing: Filed 2026-06-12; sale executed 2026-06-11

Background

The filing is an SEC Form 4 insider transaction for Alignment Healthcare, Inc. (ALHC).

Company-level read

Ticker impact

$ALHCNeutralMedium confidence
Context

Alignment Healthcare disclosed an EVP corporate affairs insider open-market sale of 25,000 shares for ~$525K under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived unless accompanied by other news.

Evidence & confidence

Form 4 shows a planned 10b5-1 sale by an officer; without accompanying company-specific operational/regulatory updates, the incremental information is limited.

Market effects

No clear sector read-through from a single planned insider sale.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect diversification/compensation mechanics rather than bearish expectations.

Key entities

  • Alignment Healthcare, Inc.

    Subject of the Form 4 insider transaction; EVP corporate affairs sold shares.

  • KONOWIECKI JOSEPH S

    EVP, Corporate Affairs; officer/director who executed the sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALHCMed

Why Alignment Healthcare (ALHC) Stock Is Up Today

Alignment Healthcare (ALHC) shares rose 8.6% after its subsidiary announced a new Medicare Advantage plan in Los Angeles and Orange counties. Analyst Ryan Langston lowered his price target to $12 but maintained a Buy rating, citing inpatient utilization pressure. The stock had fallen 13.4% the previous day due to a downgrade and regulatory concerns.

$HUMMedAI 8/10

Humana Rebounds in Medicare Advantage Star Ratings for 2027

Humana's Medicare Advantage star ratings improved significantly for 2027, with 93% of members in plans rated 4 stars or higher, up from 41% in 2026. This could generate $3B+ in additional revenue in 2028, according to TD Cowen. Alignment Healthcare saw a major decline, potentially losing $170M in revenue. CMS changed its star ratings methodology for 2027.

$ALHCHigh

ALHC Stock Slides As Legal, Cost, And Rating Pressures Mount

Alignment Healthcare Inc. (ALHC) stock fell 14.75% on October 9, 2026, amid concerns over Medicare Advantage reimbursement pressures, legal issues, and cost challenges. The company reported $1.34B in revenue and $36.6M in net income for the latest quarter, but negative cash flow raised concerns. CMS's 2027 Star Ratings and a whistleblower's accounting allegations further pressured the stock, with Barclays cutting its price target to $10.